XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in its Phase 2 open label, dose escalation clinical study evaluating its subcutaneous formulation of MABp1 in patients with moderate to severe hidradenitis suppurativa (HS), the company revealed on Tuesday.
HS is a chronic, inflammatory skin disorder that causes abscesses and scarring on the skin, affecting areas rich in apocrine glands such as the armpits, breasts and groin. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus.
Up to 4% of the global population is thought to be affected. Traditional treatments comprise of antibiotics, anti-androgens and surgery.
XBiotech is developing a human-derived antibody (MABp1) which neutralises IL-1 alpha, an inflammatory cytokine that plays a key role in the pathophysiology of a wide range of inflammatory skin disorders.
Three Phase II studies have already been completed in acne, psoriasis and pyoderma gangrenosum.
An earlier Phase 2 study evaluating MABp1 for the treatment of HS met its primary endpoint, demonstrating significant improvement of HS patients treated with MABp1 compared to control after 12 weeks of therapy. While this previous HS study involved intravenous infusion of the antibody therapy, the new trial will be the first use of the subcutaneous formulation of MABp1 in HS.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007